tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2024-14-3s1-42-48tumors-1346Research ArticleСтатьиСовременные возможности сохранения фертильности у пациенток молодого возраста. Взгляд онкологаhttps://orcid.org/0000-0003-1710-0772ПароконнаяА. А.

Анастасия Анатольевна Пароконная 

115478 Москва, Каширское шоссе, 24

ANAPAR1@yandex.ruФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Минздрава РоссииRussian Federation202418112024143s14248Copyright © Пароконная А.А., 20242024Пароконная А.А.Пароконная А.А.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/1346

В последние годы в онкологии с внедрением новых методов комплексного лечения отмечается значительное увеличение продолжительности жизни пациентов. При этом большинство используемых методов лечения потенциально гонадотоксичны и приводят к преждевременной недостаточности яичников, и соответственно к потере фертильности и способности к деторождению у молодых женщин. На момент постановки диагноза все больше пациенток задают вопросы о снижающим фертильность действии лекарственной терапии, радиотерапии, хирургических вмешательств. Недостаточная информированность онкологов и незаинтересованность в изучении вопросов, связанных с потерей репродуктивной функции, нежелание обсуждать вопросы репродукции и после лечения, приводят к психологическому стрессу и зачастую к отказу от предлагаемых вариантов терапии. Целью данной статьи является информирование онкологов о современных методах сохранения фертильности для возможности проведения ознакомительной беседы с пациентками молодого возраста перед планируемым лечением.

онкологиярепродукциябеременностькриоконсервацияфертильностьReferencesLambertini M., Peccatori F.A., Demeestere I. et.al. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2020;31(12):1664-1678. https://doi.org/10.1016/j.annonc.2020.09.006Lambertini M., Peccatori F.A., Demeestere I. et.al. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2020;31(12):1664-1678. https://doi.org/10.1016/j.annonc.2020.09.006Anderson R., Amant F., Braat D. et.al. ESHRE guideline: female fertility preservation. Hum Reprod Open 2020;2020(4):hoaa052. https://doi.org/10.1093/hropen/hoaa052Anderson R., Amant F., Braat D. et.al. ESHRE guideline: female fertility preservation. Hum Reprod Open 2020;2020(4):hoaa052. https://doi.org/10.1093/hropen/hoaa052Oktay K., Harvey B.E., Partridge A.H., et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 2018;36(19):1994-2001. https://doi.org/10.1200/JCO.2018.78.1914Oktay K., Harvey B.E., Partridge A.H., et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 2018;36(19):1994-2001. https://doi.org/10.1200/JCO.2018.78.1914Michalczyk K., Cymbaluk-Ploska A. Fertility preservation and long-term monitoring of gonadotoxicity in girls, adolescents and young adults undergoing cancer treatment. Cancers (Basel) 2021;13(2):202. https://doi.org/10.3390/cancers13020202Michalczyk K., Cymbaluk-Ploska A. Fertility preservation and long-term monitoring of gonadotoxicity in girls, adolescents and young adults undergoing cancer treatment. Cancers (Basel) 2021;13(2):202. https://doi.org/10.3390/cancers13020202Higdon R.E., Marchetti F., Mailhes J.B., Phillips G.L. The effects of cisplatin on murine metaphase II oocytes. Gynecol Oncol 1992;47(3):348-352. https://doi.org/10.1016/0090-8258(92)90138-9Higdon R.E., Marchetti F., Mailhes J.B., Phillips G.L. The effects of cisplatin on murine metaphase II oocytes. Gynecol Oncol 1992;47(3):348-352. https://doi.org/10.1016/0090-8258(92)90138-9Del-Pozo-Lerida S., Salvador C., Martinez-Soler F., et al. Preservation of fertility in patients with cancer (Review). Oncol Rep 2019;41(5):2607-2614. https://doi.org/10.3892/or.2019.7063Del-Pozo-Lerida S., Salvador C., Martinez-Soler F., et al. Preservation of fertility in patients with cancer (Review). Oncol Rep 2019;41(5):2607-2614. https://doi.org/10.3892/or.2019.7063Roness H., Kalich-Philosoph L., Meirow D. Prevention of chemotherapyinduced ovarian damage: Possible roles for hormonal and nonhormonal attenuating agents. Hum Reprod Update 2014;20(5):759-774. https://doi.org/10.1093/humupd/dmu019Roness H., Kalich-Philosoph L., Meirow D. Prevention of chemotherapyinduced ovarian damage: Possible roles for hormonal and nonhormonal attenuating agents. Hum Reprod Update 2014;20(5):759-774. https://doi.org/10.1093/humupd/dmu019Lee S.J., Schover L.R., Partridge A.H., et al. American society of clinical oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006;24(18):2917-2931. https://doi.org/10.1200/JCO.2006.06.5888Lee S.J., Schover L.R., Partridge A.H., et al. American society of clinical oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006;24(18):2917-2931. https://doi.org/10.1200/JCO.2006.06.5888Wang Y., Li Y., Liang J., et al. Chemotherapy-induced amenorrhea and its prognostic significance in premenopausal women with breast cancer: An updated meta-analysis. Front Oncol 2022;12. https://doi.org/10.3389/fonc.2022.859974Wang Y., Li Y., Liang J., et al. Chemotherapy-induced amenorrhea and its prognostic significance in premenopausal women with breast cancer: An updated meta-analysis. Front Oncol 2022;12. https://doi.org/10.3389/fonc.2022.859974Ganz P.A., Land S.R., Geyer Jr C.E., et al. Menstrual history and qualityoflife outcomes in women with nodepositive breast cancer treated with adjuvant therapy on the NSABP B30 trial. J Clin Oncol 2011;29(9):1110—1116. https://doi.org/10.1200/JCO.2010.29.7689Ganz P.A., Land S.R., Geyer Jr C.E., et al. Menstrual history and qualityoflife outcomes in women with nodepositive breast cancer treated with adjuvant therapy on the NSABP B30 trial. J Clin Oncol 2011;29(9):1110—1116. https://doi.org/10.1200/JCO.2010.29.7689Lambertini M., Ceppi M., Anderson R., et al. Impact of anti-HER2 therapy alone and with weekly paclitaxel on the ovarian reserve of young women with HER2-positive breast cancer. JNCCN 2023;21(1):33-41. https://doi.org/10.6004/jnccn.2022.7065Lambertini M., Ceppi M., Anderson R., et al. Impact of anti-HER2 therapy alone and with weekly paclitaxel on the ovarian reserve of young women with HER2-positive breast cancer. JNCCN 2023;21(1):33-41. https://doi.org/10.6004/jnccn.2022.7065Winship A.L., Alesi L.R., Sant S., et al. Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice. Nat Cancer 2022;3(8):1-13. https://doi.org/10.1038/s43018-022-00413-xWinship A.L., Alesi L.R., Sant S., et al. Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice. Nat Cancer 2022;3(8):1-13. https://doi.org/10.1038/s43018-022-00413-xBines J., Oleske D.M., Cobleigh M.A. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996;14(5):1718-1729. https://doi.org/10.1200/JCO.1996.14.5.1718Bines J., Oleske D.M., Cobleigh M.A. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996;14(5):1718-1729. https://doi.org/10.1200/JCO.1996.14.5.1718Wallace W.H.B., Anderson R.A., Irvine D.S. Fertility preservation for young patients with cancer: who is at risk and what can be offered? Lancet Oncol 2005;6(4):209-218. https://doi.org/10.1016/S1470-2045(05)70092-9Wallace W.H.B., Anderson R.A., Irvine D.S. Fertility preservation for young patients with cancer: who is at risk and what can be offered? Lancet Oncol 2005;6(4):209-218. https://doi.org/10.1016/S1470-2045(05)70092-9Walshe J.M., Denduluri N., Swain S.M. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol 2006;24(36):5769-5779. https://doi.org/10.1200/JCO.2006.07.2793Walshe J.M., Denduluri N., Swain S.M. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol 2006;24(36):5769-5779. https://doi.org/10.1200/JCO.2006.07.2793Goodwin P.J., Ennis M., Pritchard K.I., et al. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999;17(8):2365-2370. https://doi.org/10.1200/JCO.1999.178.2365Goodwin P.J., Ennis M., Pritchard K.I., et al. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999;17(8):2365-2370. https://doi.org/10.1200/JCO.1999.178.2365Petrek J.A., Naughton M.J., Case L.D., et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: aprospective study. J Clin Oncol 2006;24(7):1045-1051. https://doi.org/10.1200/JCO.2005.03.3969Petrek J.A., Naughton M.J., Case L.D., et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: aprospective study. J Clin Oncol 2006;24(7):1045-1051. https://doi.org/10.1200/JCO.2005.03.3969Lee S., Kil W.J., Chun M., et al. Chemotherapy-related amenorrhea in premenopausal women with breast cancer. Menopause 2009;16(1):98-103. https://doi.org/10.1097/gme.0b013e3181844877Lee S., Kil W.J., Chun M., et al. Chemotherapy-related amenorrhea in premenopausal women with breast cancer. Menopause 2009;16(1):98-103. https://doi.org/10.1097/gme.0b013e3181844877Ribi K., Luo W., Bernhard J., et al. Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the suppression of ovarian function trial. J Clin Oncol 2016;34(14):1601-1610. https://doi.org/10.1200/JCO.2015.64.8675Ribi K., Luo W., Bernhard J., et al. Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the suppression of ovarian function trial. J Clin Oncol 2016;34(14):1601-1610. https://doi.org/10.1200/JCO.2015.64.8675Wallace W.H.B., Thomson A.B., Saran F., Kelsey T.W. Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int J Radiat Oncol Biol Phys 2005;62(3):738-744. https://doi.org/10.1016/j.ijrobp.2004.11.038Wallace W.H.B., Thomson A.B., Saran F., Kelsey T.W. Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int J Radiat Oncol Biol Phys 2005;62(3):738-744. https://doi.org/10.1016/j.ijrobp.2004.11.038Larsen E.C., Schmiegelow K., Rechnitzer C., et al. Radiotherapy at a young age reduces uterine volume of childhood cancer survivors. Acta Obstet Gynecol Scand 2004;83(1):96-102. https://doi.org/10.1111/j.1600-0412.2004.00332.xLarsen E.C., Schmiegelow K., Rechnitzer C., et al. Radiotherapy at a young age reduces uterine volume of childhood cancer survivors. Acta Obstet Gynecol Scand 2004;83(1):96-102. https://doi.org/10.1111/j.1600-0412.2004.00332.xWallace W.H.B., Shalet S.M., Hendry J.H. et.al. Ovarian failure following abdominal irradiation in childhood: The radiosensitivity of the human oocyte. Br J Radiol 1989;62(743):995-998. https://doi.org/10.1259/0007-1285-62-743-995Wallace W.H.B., Shalet S.M., Hendry J.H. et.al. Ovarian failure following abdominal irradiation in childhood: The radiosensitivity of the human oocyte. Br J Radiol 1989;62(743):995-998. https://doi.org/10.1259/0007-1285-62-743-995Titus S., Li F., Stobezki R., et al. Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci Transl Med 2013;5(172):172ra21. https://doi.org/10.1126/scitranslmed.3004925Titus S., Li F., Stobezki R., et al. Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci Transl Med 2013;5(172):172ra21. https://doi.org/10.1126/scitranslmed.3004925Govindaraj V., Keralapura Basavaraju R., Rao A.J. Changes in the expression of DNA double strand break repair genes in primordial follicles from immature and aged rats. Reprod Biomed Online 2015;30(3):303-310. https://doi.org/10.1016/j.rbmo.2014.11.010Govindaraj V., Keralapura Basavaraju R., Rao A.J. Changes in the expression of DNA double strand break repair genes in primordial follicles from immature and aged rats. Reprod Biomed Online 2015;30(3):303-310. https://doi.org/10.1016/j.rbmo.2014.11.010Stolk L., Perry J.R.B., Chasman D.I., et al. Meta-analyses identify 13 loci associated with age at menopause and high-light DNA repair and immune pathways. Nat Genet 2012;44(3):260-268. https://doi.org/10.1038/ng.1051Stolk L., Perry J.R.B., Chasman D.I., et al. Meta-analyses identify 13 loci associated with age at menopause and high-light DNA repair and immune pathways. Nat Genet 2012;44(3):260-268. https://doi.org/10.1038/ng.1051Day F.R., Ruth K.S., Thompson D.J., et al. Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. Nat Genet 2015;47(11):1294-1303. https://doi.org/10.1038/ng.3412Day F.R., Ruth K.S., Thompson D.J., et al. Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. Nat Genet 2015;47(11):1294-1303. https://doi.org/10.1038/ng.3412Loren A.W., Mangu P.B., Beck L.N. et.al. Fertility Preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013;31(19):2500-10. https://doi.org/10.1200/JCO.2013.49.2678Loren A.W., Mangu P.B., Beck L.N. et.al. Fertility Preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013;31(19):2500-10. https://doi.org/10.1200/JCO.2013.49.2678Peccatori F.A., Azim Jr H.A., Orecchia R. et.al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24 Suppl 6:vi160-70. https://doi.org/10.1093/annonc/mdt199Peccatori F.A., Azim Jr H.A., Orecchia R. et.al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24 Suppl 6:vi160-70. https://doi.org/10.1093/annonc/mdt199Gook D.A., Edgar D.H. Human oocyte cryopreservation. Hum Reprod Update 2007;13(6):591-605. https://doi.org/10.1093/humupd/dmm028Gook D.A., Edgar D.H. Human oocyte cryopreservation. Hum Reprod Update 2007;13(6):591-605. https://doi.org/10.1093/humupd/dmm028Tian Y., Liang Y., Yang X. Successful delivery after in vitro fertilization-embryo transfer in a woman with metachro-nous primary cancer of ovary and endometrium: A case report. BMC Pregnancy Childbirth 2023;23(1):677.Tian Y., Liang Y., Yang X. Successful delivery after in vitro fertilization-embryo transfer in a woman with metachro-nous primary cancer of ovary and endometrium: A case report. BMC Pregnancy Childbirth 2023;23(1):677.Porcu E., Cipriani L., Dirodi M., et al. Successful pregnancies, births, and children development following oocyte cryostorage in female cancer patients during 25 years of fertility preservation. Cancers (Basel) 2022;14(6):1429. https://doi.org/10.3390/cancers14061429Porcu E., Cipriani L., Dirodi M., et al. Successful pregnancies, births, and children development following oocyte cryostorage in female cancer patients during 25 years of fertility preservation. Cancers (Basel) 2022;14(6):1429. https://doi.org/10.3390/cancers14061429Arecco L., Blondeaux E., Bruzzone M., et al. Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis. Hum Reprod. 2022 May 3;37(5):954-968. https://doi.org/10.1093/humrep/deac035Arecco L., Blondeaux E., Bruzzone M., et al. Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis. Hum Reprod. 2022 May 3;37(5):954-968. https://doi.org/10.1093/humrep/deac035Goldrat O., Demeestere I., Azim H. A Jr. Response to ‘Is it safe to perform a controlled ovarian stimulation for assisted reproduction in young breast cancer survivors?'. Eur J Cancer 2016;54:165-166. https://doi.org/10.1016/j.ejca.2015.10.002Goldrat O., Demeestere I., Azim H. A Jr. Response to ‘Is it safe to perform a controlled ovarian stimulation for assisted reproduction in young breast cancer survivors?'. Eur J Cancer 2016;54:165-166. https://doi.org/10.1016/j.ejca.2015.10.002Arecco L., Blondeaux E., Bruzzone M. et.al. Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis. Hum Reprod 2022;37(5):954-968. https://doi.org/10.1093/humrep/deac035Arecco L., Blondeaux E., Bruzzone M. et.al. Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis. Hum Reprod 2022;37(5):954-968. https://doi.org/10.1093/humrep/deac035Oktay K., Demirtas E., Son W.-Y. et.al. In vitro maturation of germinal vesicle oocytes recovered after premature lu-teinizing hormone surge: description of a novel approach to fertility preservation. Fertil Steril 2008;89(1):228.e19-22. https://doi.org/10.1016/j.fertnstert.2007.02.028Oktay K., Demirtas E., Son W.-Y. et.al. In vitro maturation of germinal vesicle oocytes recovered after premature lu-teinizing hormone surge: description of a novel approach to fertility preservation. Fertil Steril 2008;89(1):228.e19-22. https://doi.org/10.1016/j.fertnstert.2007.02.028Condorelli M., Bruzzone M., Ceppi M., et al. Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer. ESMO Open 2021;6(6):100300. https://doi.org/10.1016/j.esmoop.2021.100300Condorelli M., Bruzzone M., Ceppi M., et al. Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer. ESMO Open 2021;6(6):100300. https://doi.org/10.1016/j.esmoop.2021.100300Wallace W.H.B., Smith A.G., Kelsey T.W. et.al Fertility preservation for girls and young women with cancer: population-based validation of criteria for ovarian tissue cryopreservation. Lancet Oncol 2014;15(10):1129-36.Wallace W.H.B., Smith A.G., Kelsey T.W. et.al Fertility preservation for girls and young women with cancer: population-based validation of criteria for ovarian tissue cryopreservation. Lancet Oncol 2014;15(10):1129-36.Meirow D., Ra'anani H., Biderman H. Ovarian tissue cryopreservation and transplantation: a realistic, effective technology for fertility preservation. Methods Mol Biol 2014;1154:455-73. https://doi.org/10.1007/978-1-4939-0659-8_21Meirow D., Ra'anani H., Biderman H. Ovarian tissue cryopreservation and transplantation: a realistic, effective technology for fertility preservation. Methods Mol Biol 2014;1154:455-73. https://doi.org/10.1007/978-1-4939-0659-8_21Oktay K. Evidence for limiting ovarian tissue harvesting for the purpose of transplantation to women younger than 40 years of age. J Clin Endocrinol Metab 2002;87(4):1907-8. https://doi.org/10.1210/jcem.87.4.8367Oktay K. Evidence for limiting ovarian tissue harvesting for the purpose of transplantation to women younger than 40 years of age. J Clin Endocrinol Metab 2002;87(4):1907-8. https://doi.org/10.1210/jcem.87.4.8367Dolmans M.M., von Wolff M., Poirot C., et al. Transplantation of cryopreserved ovarian tissue in a series of 285 women: A review of five leading European centers. Fertil Steril 2021;115(5):1102-15. https://doi.org/10.1016/j.fertnstert.2021.03.008Dolmans M.M., von Wolff M., Poirot C., et al. Transplantation of cryopreserved ovarian tissue in a series of 285 women: A review of five leading European centers. Fertil Steril 2021;115(5):1102-15. https://doi.org/10.1016/j.fertnstert.2021.03.008Glode L.M., Robinson J., Gould S.F. Protection from cyclophosphamide-induced testicular damage with an analogue of gonadotropin-releasing hormone. Lancet 1981;1(8230):1132-1134. https://doi.org/10.1016/s0140-6736(81)92301-1Glode L.M., Robinson J., Gould S.F. Protection from cyclophosphamide-induced testicular damage with an analogue of gonadotropin-releasing hormone. Lancet 1981;1(8230):1132-1134. https://doi.org/10.1016/s0140-6736(81)92301-1Lambertini M., Moore H.C.F., Leonard R.C.F., et al. Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: A systematic review and meta-analysis of individual patient-level data. J Clin Oncol 2018;36(19):1981-1990. https://doi.org/10.1200/JCO.2018.78.0858.Lambertini M., Moore H.C.F., Leonard R.C.F., et al. Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: A systematic review and meta-analysis of individual patient-level data. J Clin Oncol 2018;36(19):1981-1990. https://doi.org/10.1200/JCO.2018.78.0858.

The authors declare that there are no conflicts of interest present.